The Wall Street Journal: Teva to buy Allergan generics for $40.5 billion

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 27 July, 2015 by The TZ Newswire Staff

The Wall Street Journal: Teva to buy Allergan generics for $40.5 billion

Teva Pharmaceutical agrees to buy Allergan PLC’s generics business for in a deal valued at $40.5 billion, making it one of the world’s biggest drugmakers, and allowing it to drop its bid for Mylan NV.
read more

See also
- Next Article Why these stocks are stuck in a rut
- Previous Article McGraw Hill to buy SNL Financial for about $2.225B
Editorial Calender

July 2015

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Jun Aug »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 27 July, 2015 by The TZ Newswire Staff

The Wall Street Journal: Teva to buy Allergan generics for $40.5 billion

See also

Editorial Calender

Recent Tags